Lakewood-Amedex Biotherapeutics Completes Redemption of Series C Convertible Preferred Stock
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) has successfully redeemed all remaining outstanding shares of its Series C Convertible Preferred Stock. The transaction, executed under an agreement with Shakawe Capital LLC, involved the redemption of 127,097 shares for a total cash payment of $1,270,970, funded entirely from the company's existing cash reserves. The move significantly simplifies the company's capital structure by eliminating all preferred stock and outstanding debt. By removing these instruments, the company eliminates the risk of future equity dilution from conversions and removes associated financing restrictions, providing management with greater financial flexibility to fund its Bisphosphocin® antimicrobial development programs.